Youhua Pharmaceutical

Youhua Pharma is a leading specialty pharmaceutical company in China, primarily focused on the Central Nervous System (CNS) therapeutic area. The company specializes in the in-licensing, clinical development, and commercialization of innovative medicines and high-end generics for the Chinese market. Youhua Pharma maintains strategic partnerships with global pharmaceutical leaders such as Lundbeck and Sandoz to market essential treatments for Alzheimer's disease, epilepsy, and depression. In 2020, the company was acquired by Hillhouse Capital for approximately $1 billion, positioning it as a core commercial platform within Hillhouse's extensive healthcare portfolio. The company operates a robust commercial infrastructure and manufacturing facilities that adhere to international GMP standards.